Progyny, Inc.
Rank #119Capital ReturnPGNY · Nasdaq · Healthcare
Progyny, Inc. (PGNY) — Rank #119 by gross profitability (GP/assets 0.43) · ROE 12.9% · Piotroski F-Score 5 / 9.
As-of 2026-09-15 · CIK 0001551306 · all metrics point-in-time as of the filing date.
About
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Show moreShow less
It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc.
was incorporated in 2008 and is headquartered in New York, New York.
- Industry
- Healthcare Plans
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- progyny.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-27 | 2024-12-31filed 2025-03-03 | 2023-12-31filed 2024-02-29 | 2022-12-31filed 2023-03-01 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 4.9 | 3.2 | 2.3 | 1.6 |
| Stock-based compensation | 131.9 | 128.1 | 122.6 | 100.7 |
| Change in receivables | 5.1 | 9.9 | 21.7 | 119.3 |
| Change in payables | 28.8 | (30.3) | 16.2 | 47.7 |
| Operating cash flow | 210.2 | 179.1 | 188.8 | 80.4 |
| Investing | ||||
| Capital expenditures | 18.4 | 5.4 | 3.6 | 3.2 |
| Acquisitions, net of cash | 9.3 | 5.3 | — | — |
| Investing cash flow | (159.0) | 195.8 | (200.5) | (43.9) |
| Financing | ||||
| Share repurchases | 81.7 | 300.3 | — | — |
| Financing cash flow | (99.4) | (309.9) | (11.1) | (7.9) |
| Summary | ||||
| Free cash flow | 191.8 | 173.7 | 185.2 | 77.2 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?